ArticleMolecular medicine (Cambridge, Mass.)2026
Neuronal surface P antigen (NSPA) as a novel regulator of energy homeostasis and adipose tissue metabolism.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRegulation of body weight and glucose homeostasis includes the coordinated activity of hypothalamic neurons and adipocytes within a neuroendocrine network whose dysfunctions underlie obesity, insulin resistance, and type 2 diabetes (T2D). The neuronal surface P antigen (NSPA) is a plasma membrane protein with characteristics of an E3 ubiquitin ligase encoded by the unique gene Zzef1, which has been linked to T2D. NSPA's original discovery in neurons, as a cell-surface cross-reacting autoantigen of anti-P antibodies that associate with cognitive dysfunctions in patients with systemic lupus erythematosus, focused its study on hippocampal-mediated memory processes. Anti-P effects and NSPA-KO mice revealed that NSPA contributes to glutamatergic transmission and synaptic plasticity through mechanisms involving ubiquitylation processes coupled to the stability of NMDAR at the synaptic density. However, NSPA is also expressed in hypothalamic neurons, where glutamatergic synapses and NMDAR function are pivotal to the neuroendocrine control of metabolic and energy balance. Transcriptomics suggests an extended expression of NSPA in metabolically relevant peripheral tissues, including the adipose tissue. Here, we investigated whether body weight regulation and energy homeostasis involve NSPA.
methodsWe characterized the phenotype of NSPA-KO mice under standard chow and high-fat/high-sugar (HFHS) obesogenic diet conditions, monitoring metabolic parameters and WAT's expression of enzymes and transporters of the glucose metabolism and lipolysis.
resultsNSPA-KO mice exhibit: (i) Increased body weight gain, despite similar food intake and higher horizontal locomotion activity; (ii) A shift towards a glycolytic metabolism reflected in an increased RER, accompanied by an increased WAT mass indicating higher lipogenesis; (iii) Improved early glycemic response to glucose challenge, attenuating the acute glycemic rise induced by HFHS feeding; (iv) Reduced insulin sensitivity at 20 weeks of age; (v) Elevated Glut1 and LDH, with decreased Glut4, and HSL S563 phosphorylation in WAT, indicating altered glucose uptake, glycolysis and lipolysis; (vi) Decreased levels of phosphorylated STAT3 in the hypothalamus, suggesting attenuated leptin signaling.
conclusionsThis study identifies NSPA as a novel regulator of energy homeostasis, body weight, glucose metabolism, insulin sensitivity, and adipose tissue accumulation, presumably acting at both the hypothalamus and WAT, with potential implications for obesity and metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.